Powered by: Motilal Oswal
9/03/2021 9:40:14 AM | Source: Motilal Oswal Financial Services Ltd
Healthcare Sector Update - IPM growth moderates further in Feb`21 By Motilal Oswal
News By Tags | #4315 #3062
Healthcare Sector Update - IPM growth moderates further in Feb`21 By Motilal Oswal

IPM growth moderates further in Feb’21

* IPM growth moderated further to 1.1% YoY in Feb’21 v/s 4.5% YoY in Jan’21 (12.1% in Feb’20).

* The Gastro, Derma, and VMN therapies exhibited growth of 9.9% YoY, 9.6% YoY, and 8.6% YoY, respectively. The Anti-Infective therapy declined 11.3% YoY vis-àvis decline of 2.7% YoY in Jan’21.

* Respiratory sales continued on the downtrend with 20.3% YoY decline in Feb’21.

* NLEM (~16% of IPM) declined 3% YoY, while non-NLEM (~84% of IPM) grew 2% YoY.

* On a MAT basis, industry growth came in at 1.9% YoY.

 

Price/NP growth offsets volume decline for 3M ended Feb’21

* For the 3M ended Feb’21, YoY growth stood at 4.7% YoY. YoY price growth of 4.9% and NP growth of 2.6% was offset, to some extent, by a YoY drop of 2.8% in volumes.

* For the 3M ended Feb’21, NLEM (~17% of IPM) grew 1.4% YoY and non-NLEM (~83% of IPM) was up 5.4% YoY.

 

Merck, Wockhardt, Ajanta, JB Chemicals, Biocon, and Ipca outperform

* In Feb’21, Merck India (+22.7% YoY), Wockhardt (+20% YoY), Ajanta Pharma (+15.7% YoY), JB Chemicals (+11.7% YoY), Biocon (+10% YoY), and Ipca (+9.7% YoY) delivered robust performances.

* Ajanta grew on a strong offtake in the Cardiac and Pain therapies (~50% of the therapy mix) of 20% and 22.7% YoY, respectively.

* Biocon’s growth was driven by Anti-Infectsives/Anti-Neoplasts (+75%/+22.6% YoY).

* Ipca posted good traction in the Pain/Analgesics (+20.5% YoY) and Gastro (22.2% YoY) segments.

* Lupin / Alembic / Dr Reddy’s reported below industry growth in Feb’21 (+0.5%/- 2.8%/-7.9% YoY) v/s +4.6%/+4.3/-3.6% in Jan’21.

* On a MAT basis, JB Chemicals / Merck / Torrent reported the highest price growth (+10.4%/7.5%/7% YoY). Glenmark saw the highest growth in new launches (+14.9% YoY).

 

Cardiac, Anti-Diabetic, and VMN drive overall sales growth on a MAT basis

* Chronic therapies saw strong growth – Cardiac / Anti-diabetic / VMN therapies exhibited growth of 12.5%/7.1%/6.7% YoY.

* Respiratory/Pain/Gynaec sales declined 5.4%/3.5%/3.2 YoY, impacting overall growth.

 

 

 

To Read Complete Report & Disclaimer Click Here

 

For More Motilal Oswal Securities Ltd Disclaimer http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html SEBI Registration number is INH000000412

 

Above views are of the author and not of the website kindly read disclaimer

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here